In heart failure (HF), a defective nitric oxide (NO) signaling may be involved in left
ventricular (LV) diastolic abnormalities and LV remodelling progression. PDE5-inhibition, by
blocking NO degradation and overexpressing cellular cyclic guanosine monophosphate (cGMP)
pathways might be beneficial. Several short term studies have demonstrated safety and
clinical improvement in stable heart failure (HF) patients.
The purpose of this study is to test the effects on LV diastolic function, cardiac geometry
and clinical status in a cohort of HF patients.